Market access barriers

This report from Medicines for Europe from October, 2024 outlines key barriers that prevent biosimilar and generic medicines from reaching patients even after regulatory approval. It highlights delays caused by legal tactics, pricing rules, and market conditions that maintain brand-name monopolies.